Organised in partnership with:

Advanced Therapies – Opportunities and Challenges

Click on the name of the speaker to download the slide deck

Peter Goodfellow, Scientific Advisor, Abingworth
“Regenerating the Future, Again”
Ian Campbell, Director for Health and Life Sciences, Innovate UK
“Innovate UK Supporting Research Development & Manufacturing in Advanced Therapies”
Christian K Schneider, Director, National Institute for Biological Standards and Control (NIBSC)
“Advanced Therapies – regulatory challenges”

Seigo Izumo, Senior Vice President for Regenerative Medicine, Takeda Pharmaceuticals
Eduardo Bravo, Chief Executive Officer, TiGenix; EBE President
Qasim Rafiq, Senior Lecturer (Associate Professor) in Bioprocessing of Regenerative, Cellular and Gene Therapies, UCL
Keith Thompson, Chief Executive Officer, Cell and Gene Therapy Catapult

Michaël Hocquemiller, Scientific Director, Lysogene
“Pioneering gene therapies for CNS disorders”
Adrien Lemoine, VP Business Development & Operations, Orchard Therapeutics
“Overcoming the complex challenges associated with the development of ex vivo gene therapies for rare diseases”
Karen Hodgkin, Chief Operating Officer, Cell Medica
“Cell Medica: Novel approaches for the treatment of Solid Tumours”
James McBlane, CAT Alternate Member, Preclinical Assessor, UK Medicines and Healthcare Products Regulatory Agency (MHRA)
“Partnering well together – creating a global ecosystem for advanced therapies”

Magda Papadaki, Head of Product and Process Innovation, Association of the British Pharmaceutical Industry (ABPI)
Barbara Freischem, Executive Director, European Biopharmaceutical Enterprises (EBE)
Deborah Morrison, Senior Scientific Adviser, National Institute for Health and Care Excellence (NICE)
Michael Stein, Chief Executive Officer and Chairman, Oxstem Ltd